Ranked among the top 10 best hospitals in the world for five consecutive years, Sheba Hospital in Israel has become a leader in CAR-T therapy. Offering innovative, in-house, point-of-care academic CAR-T treatments, Sheba Hospital is revolutionizing cancer treatment.
At Sheba Hospital, patients often find that they don't need bridging therapy, making the treatment process smoother. Three specialized programs, each catering to different patient needs, highlight the hospital's dedication to cutting-edge cancer care.
Starting in 2016, the hospital launched its first initiative focusing on pediatric Acute Lymphoblastic Leukemia (ALL), expanding the program to adults a year later. Lymphoma patients represent a significant majority of those enrolled in this program.
In November 2021, Sheba introduced a new program centered on multiple myeloma, targeting the anti-B-cell maturation antigen. Furthermore, the hospital runs a unique small-scale clinical trial for a specific Acute Myeloid Leukemia (AML) category – those with A21 translocation expressing CD19. This specialized program, which has treated six patients, sets Sheba apart as an innovator in CAR-T therapy.
Recognized as the biggest CAR-T center in Europe, Sheba's activity level is evident in data from the European Bone Marrow Transplantation (EBMT) organization. The hospital's dedication to CAR-T therapy is reflected in the large number of patients treated.
As of May 2023, Sheba Hospital has treated 258 patients, including 189 adults and 69 pediatric patients. Among these, 189 have been diagnosed with lymphatic malignancies, and six with Acute Myeloid Leukemia (AML).
The benefits of Sheba's in-house academic CAR-T therapy are numerous. Increased accessibility and affordability make it a cost-effective option for most patients. Moreover, the therapy is typically administered within 11 days, often eliminating the need for bridging therapy and potentially leading to improved patient outcomes.
With a focus on innovation and patient-centered care, Sheba Hospital is changing the face of cancer treatment.
The cost of the CART cell procedure in Sheba is $80,000-$120,000 USD.
CAR-T in Israel - patients testimonials:
CAR-T patient testimonial:
CAR-T patient testimonial:
Doctor Abraham Avigdor, director of Sheba's Hematology department in an interview for Israeli TV. (Hebrew with English captions)
TV program. Hebrew with English subtitles. CAR-T therapy - new treatment for blood cancers and Lymphoma
CAR T patients in Israel with our guide
